On Tuesday, Shares of Comcast Corporation (NASDAQ:CMCSA), lost -0.76% to $57.33.
Comcast Corporation, declared that its full portfolio of Ethernet services is now accessible to businesses in Portland’s Central Eastside, a district of the city presently undergoing growth as companies take advantage of the area’s distinctive warehouses and industrial buildings. Through the expansion of Comcast’s Ethernet network, local businesses now have access to bandwidth of up to 10 Gigabits-per-second (Gbps) and services specifically designed to assist companies of all sizes access fast, reliable Internet service or connect multiple locations together or to an offsite data center.
Comcast Corporation operates as a media and technology company worldwide. It operates through Cable Communications, Cable Networks, Broadcast Television, Filmed Entertainment, and Theme Parks segments. The Cable Communications segment offers video, high-speed Internet, and voice services to residential and business customers under the XFINITY brand name.
Shares of Glu Mobile, Inc. (NASDAQ:GLUU), declined -1.93% to $6.59, during its last trading session.
Glu Mobile, declared that on May 11, 2015, its Compensation Committee awarded restricted stock units covering an aggregate of 41,600 shares of Glu’s common stock to 13 newly hired employees following Glu’s 2008 Equity Inducement Plan. Each of the restricted stock unit awards vests on a four-year plan – 25% of the underlying shares will vest on May 15, 2016, with the remaining 75% of the underlying shares vesting in equal quarterly installments over the next three years on the same day of each third month (e.g., the next quarterly vesting date will be August 15, 2016, then November 15, 2016, etc.).
Glu Mobile Inc. develops, publishes, and markets a portfolio of games for the smartphones and tablet devices users. The company offers free-to-play action, casual, racing, and sports genre mobile games.
At the end of Tuesday’s trade, Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), gained 10.07% to $6.67.
Spectrum Pharmaceuticals, declared financial results for the three-month period ended March 31, 2015.
Three-Month Period Ended March 31, 2015 (All numbers are approximate)
GAAP Results
Total product sales were $38.4 million (not taking into account $7 million in deferred revenue) in the first quarter of 2015. Total product sales reduced 4% from $40.1 million in the first quarter of 2014.
Product sales in the first quarter comprised of: FUSILEV® (levoleucovorin) net sales of $20.2 million, FOLOTYN® (pralatrexate injection) net sales of $9.3 million, ZEVALIN® (ibritumomab tiuxetan) net sales of $4.2 million, MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $1.9 million and BELEODAQ® (belinostat) for Injection net sales of $2.8 million.
Spectrum recorded net loss of $25.6 million, or ($0.39) per basic and diluted share in the three-month period ended March 31, 2015, contrast to net loss of $27.6 million, or ($0.44) per basic and diluted share in the comparable period in 2014. Total research and development expenses were $15.9 million in the quarter, as contrast to $29.5 million in the same period in 2014 which comprised of a $17.8 million milestone payment. Selling, general and administrative expenses were $23.3 million in the quarter, contrast to $23.4 million in the same period in 2014.
Non-GAAP Results
Spectrum recorded non-GAAP net loss of $4.7 million, or ($0.07) per basic share and diluted share in the three-month period ended March 31, 2015, contrast to non-GAAP net income of $0.7 million, or $0.01 per basic share and diluted share in the comparable period in 2014. Non-GAAP research and development expenses were $12.4 million, as contrast to $11.2 million in the same period of 2014. Non-GAAP selling, general and administrative expenses were $22.9 million, as contrast to $20.7 million in the same period in 2014.
Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company markets five drug products, counting FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.
Finally, Cobalt International Energy, Inc. (NYSE:CIE), ended its last trade with 4.15% gain, and closed at $11.04.
Cobalt International Energy, declared a net loss of $82 million, or $0.20 per basic and diluted share for the first quarter of 2015, contrast to a net loss of $57 million, or $0.14 per basic and diluted share, for the first quarter of 2014. The current quarter comprised of $17 million of impairment charges for the formerly declared abandonment of the North Platte #2 appraisal well.
Capital and operating expenditures (not taking into account changes in working capital) for the quarter ending March 31, 2015 were about $191 million, in line with our planned capital and operating expenditures of about $800-900 million in 2015. Cash, cash equivalents, and investments at the end of the first quarter were about $2.1 billion. This comprises about $105 million held for future operations in collateralizing letters of credit.
Cobalt International Energy, Inc., through its auxiliaries, engages in the exploration and production of oil-focused, below-salt exploration prospects. Its project portfolio comprises North Platte, Heidelberg, Shenandoah, and Anchor discovery in the U.S. Gulf of Mexico; Cameia, Lontra, Mavinga, Bicuar, and Orca in the offshore Angola; and Diaman in the offshore Gabon.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
